共 50 条
- [41] Is the "lipid paradox" in rheumatoid arthritis really a paradox? Comment on the article by Bartels et al ARTHRITIS AND RHEUMATISM, 2011, 63 (11): : 3644 - 3645
- [42] Dose-loading with hydroxychloroquine in rheumatoid arthritis: comment on the article by Furst et al ARTHRITIS AND RHEUMATISM, 1999, 42 (07): : 1556 - 1556
- [44] Severity of rheumatoid arthritis in Portuguese patients: comment on the article by Drosos et al and on the letter by Ronda et al - Reply ARTHRITIS AND RHEUMATISM, 2000, 43 (02): : 471 - 472
- [45] Interpreting the results of a segregation analysis of generalized radiographic osteoarthritis: Comment on the article by Felson et al ARTHRITIS AND RHEUMATISM, 1999, 42 (05): : 1068 - 1069
- [47] The heart in rheumatoid arthritis: contrasting or misleading data from clinical research? Comment on the article by Giles et al Reply ARTHRITIS AND RHEUMATISM, 2010, 62 (12): : 3834 - 3835
- [48] Selective estrogen receptor agonism lacks clinical benefit in rheumatoid arthritis: comment on the article by van Vollenhoven et al ARTHRITIS AND RHEUMATISM, 2010, 62 (12): : 3832 - 3833
- [49] A suggestion and the larger perspective on the American College of Rheumatology/European League Against Rheumatism remission definitions: comment on the article by Felson et al Reply ARTHRITIS AND RHEUMATISM, 2011, 63 (11): : 3644 - 3644
- [50] Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al ARTHRITIS AND RHEUMATISM, 2010, 62 (09): : 2826 - 2826